A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Reprocessing N95 Masks With STERRAD: Protects Healthcare Workers in the Battle Against COVID-19

The Company ADVANCED STERILIZATION PRODUCTS Thanks FDA for New Guidance to Expedite Solutions in Order to Protect the Public

Advanced Sterilization Products has qualified a new reprocessing protocol that can extend the lifespan of single-use N95 masks (respirators) utilizing STERRAD® Systems already available in most US hospitals and globally.

The evolution of the COVID-19 pandemic has created a mass shortage of N95 masks for healthcare professionals around the world. ASP qualified a protocol for reprocessing select N95 masks so hospitals can triple the lifespan of the mask using the STERRAD® Sterilizers already in healthcare facilities today to reprocess up to 480 masks per STERRAD® Sterilizer machine daily to help healthcare professionals combat the spread of coronavirus.

“We are a company dedicated to keeping people safe, so we are proud to bring forth this new protocol to help extend the functionality of mission-essential N95 masks at this critical time,” said Dominic Ivankovich, President of ASP. “We are committed to provide support to the medical community and continue to work closely with them to implement this new protocol to help keep our HCP heroes safer as they remain at the front-lines in the battle against COVID-19.”

All ASP sterilization systems and disinfectant solutions have been tested against enveloped viruses, the family of viruses that includes coronavirus, and have been demonstrated to be efficacious against those viruses. ASP’s new qualified protocol uses technology already in place in most hospitals to now reprocess certain N95 masks.

“ASP feels responsible to help discover solutions that will aid frontline responders to remain safe in fighting back this pandemic,” said Jeremy Yarwood, Vice President Research & Development, ASP. “The new FDA guidance has allowed us go public with our qualified solution quickly so we can join the effort to overcome shortages of personal protection equipment for healthcare workers worldwide.”

Visit asp.com for complete and up-to-date information on PPE reprocessing, instructions for use of the N95 reprocessing protocol, and 8 Things to consider before reprocessing N95 masks/respirators.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy